Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | KRAS | P01116 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13263822 | 0.80 | PTGS2 (0.58) | PTGS2TLR9PTGS1CYP19A1KRAS | |
| SCHEMBL2618843 | 0.80 | PTGS2 (0.54) | PTGS2TLR9PTGS1CYP19A1KRAS | |
| SCHEMBL726164 | 0.76 | PTGS2 (0.52) | PTGS2TLR9PTGS1CYP19A1KRAS | |
| SCHEMBL2111797 | 0.76 | PTGS2 (0.52) | PTGS2TLR9PTGS1CYP19A1KRAS | |
| SCHEMBL6765969 | 0.74 | ERN1 (0.43) | — | |
| SCHEMBL4257030 | 0.70 | PTGS2 (0.53) | PTGS2TLR9PTGS1CYP19A1KRAS | |
| SCHEMBL3054757 | 0.69 | TLR9 (0.76) | PTGS2TLR9PTGS1CYP19A1KRAS | |
| SCHEMBL3054759 | 0.69 | TLR9 (0.76) | PTGS2TLR9PTGS1CYP19A1KRAS | |
| SCHEMBL4263095 | 0.69 | PTGS2 (0.68) | PTGS2TLR9PTGS1CYP19A1KRAS | |
| SCHEMBL4263101 | 0.69 | PTGS2 (0.68) | PTGS2TLR9PTGS1CYP19A1KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | PTGS2 4240/4885TLR9 2861/4885PTGS1 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.